Historical Valuation
Rigel Pharmaceuticals Inc (RIGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.88 is considered Undervalued compared with the five-year average of -5.08. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 194.20 to 237.77 according to relative valuation methord. Compared to the current price of 44.50 USD , Rigel Pharmaceuticals Inc is Undervalued By 77.09%.
Relative Value
Fair Zone
194.20-237.77
Current Price：44.50
77.09%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Rigel Pharmaceuticals Inc (RIGL) has a current Price-to-Book (P/B) ratio of 6.45. Compared to its 3-year average P/B ratio of -0.29 , the current P/B ratio is approximately -2342.26% higher. Relative to its 5-year average P/B ratio of 1.77, the current P/B ratio is about 265.12% higher. Rigel Pharmaceuticals Inc (RIGL) has a Forward Free Cash Flow (FCF) yield of approximately 8.97%. Compared to its 3-year average FCF yield of -4.22%, the current FCF yield is approximately -312.76% lower. Relative to its 5-year average FCF yield of -7.40% , the current FCF yield is about -221.30% lower.
P/B
Median3y
-0.29
Median5y
1.77
FCF Yield
Median3y
-4.22
Median5y
-7.40
Competitors Valuation Multiple
AI Analysis for RIGL
The average P/S ratio for RIGL competitors is 51.13, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL.O) exhibits a P/S ratio of 2.88, which is -94.36% above the industry average. Given its robust revenue growth of 25.59%, this premium appears sustainable.
Performance Decomposition
AI Analysis for RIGL
1Y
3Y
5Y
Market capitalization of RIGL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RIGL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RIGL currently overvalued or undervalued?
Rigel Pharmaceuticals Inc (RIGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.88 is considered Undervalued compared with the five-year average of -5.08. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 194.20 to 237.77 according to relative valuation methord. Compared to the current price of 44.50 USD , Rigel Pharmaceuticals Inc is Undervalued By 77.09% .
What is Rigel Pharmaceuticals Inc (RIGL) fair value?
RIGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 194.20 to 237.77 according to relative valuation methord.
How does RIGL's valuation metrics compare to the industry average?
The average P/S ratio for RIGL's competitors is 51.13, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL) exhibits a P/S ratio of 2.88, which is -94.36% above the industry average. Given its robust revenue growth of 25.59%, this premium appears sustainable.
What is the current P/B ratio for Rigel Pharmaceuticals Inc (RIGL) as of Jan 10 2026?
As of Jan 10 2026, Rigel Pharmaceuticals Inc (RIGL) has a P/B ratio of 6.45. This indicates that the market values RIGL at 6.45 times its book value.
What is the current FCF Yield for Rigel Pharmaceuticals Inc (RIGL) as of Jan 10 2026?
As of Jan 10 2026, Rigel Pharmaceuticals Inc (RIGL) has a FCF Yield of 8.97%. This means that for every dollar of Rigel Pharmaceuticals Inc’s market capitalization, the company generates 8.97 cents in free cash flow.
What is the current Forward P/E ratio for Rigel Pharmaceuticals Inc (RIGL) as of Jan 10 2026?
As of Jan 10 2026, Rigel Pharmaceuticals Inc (RIGL) has a Forward P/E ratio of 10.25. This means the market is willing to pay $10.25 for every dollar of Rigel Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Rigel Pharmaceuticals Inc (RIGL) as of Jan 10 2026?
As of Jan 10 2026, Rigel Pharmaceuticals Inc (RIGL) has a Forward P/S ratio of 2.88. This means the market is valuing RIGL at $2.88 for every dollar of expected revenue over the next 12 months.